LAUSR

Combination therapy is a promising approach for effective treatment of tumors through synergistically regulating pathways. However, the synergistic effect is limited, likely by uncontrolled co‐delivery of different therapeutic payloads in a single nanoparticle. Herein, a combination nanotherapeutic is developed by using two amphiphilic conjugates, hyperbranched poly(ethylene glycol)–pyropheophorbide‐a (Ppa) (HP‐P) and hyperbranched poly(ethylene glycol)–doxorubicin (DOX) (HP‐D) to construct co‐assembly nanoparticles (HP‐PD NPs) for controllably co‐loading and co‐delivering Ppa and DOX. In vitro and in vivo antitumor studies confirm the synergistic effect of photodynamic therapy and chemotherapy from HP‐PD NPs. Metabolic variations reveal that tumor suppression is associated with disruption of metabolic homeostasis, leading to reduced protein translation. This study uncovers the manipulation of metabolic changes in tumor cells through disruption of cellular homeostasis using HP‐PD NPs and provides a new insight into the rational design of synergistic nanotherapeutics for combination therapy.